Welcome, Guest. Please login or register.
July 14, 2024, 12:10:06 pm

Login with username, password and session length

  • Total Posts: 55130
  • Total Topics: 4851
  • Online Today: 237
  • Online Ever: 1314
  • (June 22, 2016, 05:23:42 am)
Users Online
Users: 0
Guests: 114
Total: 114


Welcome to the Hep Forums, a round-the-clock discussion area for people who have Fatty Liver Disease, Hepatitis B, C or a co-infection, their friends and family and others with questions about hepatitis and liver health. Check in frequently to read what others have to say, post your comments, and hopefully learn more about how you can reach your own health goals.

Privacy Warning: Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.
  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.
  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.
  • Product advertisement (including links); banners; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from the Hep Forum Moderators.
Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Combo of Gastric Acid Drugs Plus Harvoni or Epclusa Tied to High Hep C Cure Rate  (Read 5429 times)

0 Members and 1 Guest are viewing this topic.

Offline Hep Editors

  • Member
  • Posts: 784
    • Hep Mag
People with cirrhosis who were treated for hepatitis C virus (HCV) with Harvoni (ledipasvir/sofosbuvir) or Epclusa (sofosbuvir/velpatasvir) and who received intravenous (IV) proton pump inhibitors (PPIs) or histamine H2 agonists were cured of the virus at a high rate in a recent small study, the National AIDS Treatment Advocacy Project (NATAP) reports. This occurred despite the fact that such gastric acid drugs are known to lower the concentrations of the ledipasvir and velpatasvir components of the respective combination direct-acting antiviral (DAA) tablets.

Presenting their findings at the 20thInternational Workshop on Clinical Pharmacology of HIV, Hepatitis & Other Antiviral Drugs in Noordwyk, the Netherlands, researchers at the University of Montreal conducted a study of 11 people with HCV from the MONTREAL-C study.



© 2024 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.